Article summary
An industry wide look at how neuroplastogens are reshaping psychedelic medicine in 2026, with insights on Delix, AbbVie’s Gilgamesh acquisition, Enveric, and the shift toward nonhallucinogenic brain therapeutics. The post Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative appeared first on Microdose.
Continue to the original publication for the complete article.